MedTrace Logo

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

NCT00500578 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-08-01

Study results available
· View outcomes & findings →

Summary

Primary Objectives:

1. To determine whether aerosolized ribavirin is effective when given at an intermittent dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection (URI) and whether it can prevent progression to pneumonia.
2. To determine the effect of this regimen on persistence of viral shedding.

Conditions

Interventions

DRUG

Ribavirin

Arm 1 = 6 Grams Over 18 hours Every 24 Hours

DRUG

Ribavirin

Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.

Sponsors & Collaborators

  • ICN Pharmaceuticals

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Roy F. Chemaly, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500578 on ClinicalTrials.gov